356 related articles for article (PubMed ID: 24628659)
1. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
Shi S; Tao L; Song H; Chen L; Huang G
APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
[TBL] [Abstract][Full Text] [Related]
2. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.
Tao L; Huang G; Shi S; Chen L
Med Oncol; 2014 Jan; 31(1):777. PubMed ID: 24271420
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
[TBL] [Abstract][Full Text] [Related]
5. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model.
Wu H; Xin Y; Zhao J; Sun D; Li W; Hu Y; Wang S
Cancer Chemother Pharmacol; 2011 Oct; 68(4):879-87. PubMed ID: 21290245
[TBL] [Abstract][Full Text] [Related]
6. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts.
Zhang M; Tao W; Pan S; Sun X; Jiang H
Anticancer Drugs; 2009 Jun; 20(5):355-63. PubMed ID: 19318912
[TBL] [Abstract][Full Text] [Related]
7. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model.
Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y
Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809
[TBL] [Abstract][Full Text] [Related]
8. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Ng SS; Sparreboom A; Shaked Y; Lee C; Man S; Desai N; Soon-Shiong P; Figg WD; Kerbel RS
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4331-8. PubMed ID: 16857808
[TBL] [Abstract][Full Text] [Related]
9. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-15-transferred cytokine-induced killer cells elevated anti-tumor activity in a gastric tumor-bearing nude mice model.
Peng Z; Liang W; Li Z; Xu Y; Chen L
Cell Biol Int; 2016 Feb; 40(2):204-13. PubMed ID: 26503216
[TBL] [Abstract][Full Text] [Related]
11. Calreticulin promotes tumor lymphocyte infiltration and enhances the antitumor effects of immunotherapy by up-regulating the endothelial expression of adhesion molecules.
Wang HT; Lee HI; Guo JH; Chen SH; Liao ZK; Huang KW; Torng PL; Hwang LH
Int J Cancer; 2012 Jun; 130(12):2892-902. PubMed ID: 21805477
[TBL] [Abstract][Full Text] [Related]
12. [Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy].
Shi M; Yao L; Wang FS; Lei ZY; Zhang B; Li WL; Liu JC; Tang ZR; Zhou GD
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):465-8. PubMed ID: 15555334
[TBL] [Abstract][Full Text] [Related]
13. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
Yuan F; Shi H; Ji J; Cai Q; Chen X; Yu Y; Liu B; Zhu Z; Zhang J
Oncol Rep; 2015 Apr; 33(4):1753-62. PubMed ID: 25634241
[TBL] [Abstract][Full Text] [Related]
15. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy.
Huber PE; Bischof M; Jenne J; Heiland S; Peschke P; Saffrich R; Gröne HJ; Debus J; Lipson KE; Abdollahi A
Cancer Res; 2005 May; 65(9):3643-55. PubMed ID: 15867359
[TBL] [Abstract][Full Text] [Related]
16. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
[TBL] [Abstract][Full Text] [Related]
17. Preconditioning chemotherapy with paclitaxel and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model.
Huang X; Huang G; Song H; Chen L
Int J Cancer; 2011 Aug; 129(3):648-58. PubMed ID: 20878978
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Wu C; Jiang J; Shi L; Xu N
Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
[TBL] [Abstract][Full Text] [Related]
20. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma.
Jin J; Joo KM; Lee SJ; Jo MY; Kim Y; Jin Y; Kim JK; Ahn JM; Yoon MJ; Lim J; Nam DH
Oncol Rep; 2011 Jan; 25(1):33-9. PubMed ID: 21109954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
